|
Our patented rivastigmine nasal spray has the potential to improve the efficacy, tolerability and convenience of this class of drugs known as cholinesterase inhibitors.
First human study of nasal absorption of a cholinesterase inhibitor (rivastigmine)
|
Initial clinical trial results
Morgan TM, Soh B. Absolute Bioavailability and Safety of a Novel Rivastigmine Nasal Spray in Healthy Elderly Individuals. Br J Clin Pharmacol. 2017 83(3):510-516 PMID: 27639640 DOI: 10.1111/bcp.13133 ANZCTR reference: ACTRN12614001313628
Other opportunities
Organophosphorus poisoning treatment
Existing nerve agent antidotes lack sufficient entry to brain so soldiers may be at-risk of post-exposure seizures and neuronal damage. Rivastigmine readily enters the brain so it has potential to treat and/or prevent organophosphorus poisoning.
Important note: All the drug candidates above are not yet approved by any regulatory agency for commercial sale and use in humans in any country, territory or jurisdiction.
Existing nerve agent antidotes lack sufficient entry to brain so soldiers may be at-risk of post-exposure seizures and neuronal damage. Rivastigmine readily enters the brain so it has potential to treat and/or prevent organophosphorus poisoning.
Important note: All the drug candidates above are not yet approved by any regulatory agency for commercial sale and use in humans in any country, territory or jurisdiction.